Docoh
Loading...

HZNP Horizon Therapeutics

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Company profile

Ticker
HZNP
Exchange
CEO
Timothy P. Walbert
Employees
Incorporated
Location
Fiscal year end
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
IRS number
272179987

HZNP stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

24 Feb 21
25 Feb 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Feb 21 Karnani Vikram Ordinary Shares Sell Dispose S No Yes 88.4502 645 57.05K 104,165
22 Feb 21 Karnani Vikram Ordinary Shares Sell Dispose S No Yes 87.083 7,713 671.67K 104,810
22 Feb 21 Konstantinovsky Irina Ordinary Shares Sell Dispose S No Yes 88.4986 474 41.95K 81,677
22 Feb 21 Konstantinovsky Irina Ordinary Shares Sell Dispose S No Yes 87.1055 5,224 455.04K 82,151
21 Feb 21 DesJardin Michael A. Ordinary Shares Payment of exercise Dispose F No No 88.87 1,082 96.16K 103,290
21 Feb 21 DesJardin Michael A. Ordinary Shares Option exercise Aquire M No No 0 2,182 0 104,372
21 Feb 21 DesJardin Michael A. RSU Ordinary Shares Option exercise Dispose M No No 0 2,182 0 0
21 Feb 21 Daniel A. Camardo Ordinary Shares Payment of exercise Dispose F No No 88.87 576 51.19K 45,800
21 Feb 21 Daniel A. Camardo Ordinary Shares Option exercise Aquire M No No 0 1,300 0 46,376
21 Feb 21 Daniel A. Camardo RSU Ordinary Shares Option exercise Dispose M No No 0 1,300 0 0
88.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 464 423 +9.7%
Opened positions 110 116 -5.2%
Closed positions 69 39 +76.9%
Increased positions 165 148 +11.5%
Reduced positions 155 136 +14.0%
13F shares
Current Prev Q Change
Total value 17.46B 15.12B +15.5%
Total shares 196.32M 194.62M +0.9%
Total puts 1.39M 1.15M +20.5%
Total calls 3.9M 1.11M +249.5%
Total put/call ratio 0.4 1.0 -65.5%
Largest owners
Shares Value Change
Vanguard 19.92M $1.46B +3.5%
BLK Blackrock 14.21M $1.04B +23.0%
FMR 13.25M $969.49M -19.1%
Avoro Capital Advisors 9M $658.35M +17.6%
JHG Janus Henderson 8.19M $599.29M -8.3%
Paulson & Co. 7.99M $584.57M +19.4%
Renaissance Technologies 6.8M $497.34M -22.6%
JPM JPMorgan Chase & Co. 5.91M $432.17M +14.5%
William Blair Investment Management 5.25M $384.33M -10.2%
STT State Street 4.41M $322.96M +76.7%
Largest transactions
Shares Bought/sold Change
FMR 13.25M -3.13M -19.1%
Perceptive Advisors 3.08M +3.08M NEW
BLK Blackrock 14.21M +2.65M +23.0%
Viking Global Investors 3.66M +2.49M +212.1%
Renaissance Technologies 6.8M -1.98M -22.6%
STT State Street 4.41M +1.92M +76.7%
Polar Capital 1.84M +1.84M NEW
Deerfield Management 0 -1.83M EXIT
IVZ Invesco 716.38K -1.74M -70.8%
POLR Polar Capital 0 -1.5M EXIT

Financial report summary

?
Management Discussion
  • Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.  You should read the “Risk Factors” section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
  • Unless otherwise indicated or the context otherwise requires, references to “Horizon”, “we”, “us” and “our” refer to Horizon Therapeutics plc and its consolidated subsidiaries.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: advocacy, agenda, agile, Aid, aiding, Aisling, allyship, amplified, analyzed, Anchen, anesthesiologist, Annora, antagonism, antagonist, Aon, appointing, Appointment, attack, autoantibody, belatacept, bidding, Biden, Biovitrum, Boulder, Britain, broadcast, burnout, buy, Cadillac, calcineurin, Camardo, campaign, cap, capita, capped, caregiver, CEO, Certiorari, characterized, charity, Chase, Chicago, child, cholesterol, Citigroup, CJEU, club, coaching, college, Colorado, comment, constitutionality, copay, Copenhagen, courier, CPRA, Crain, Curzion, dcSSc, demographic, dendritic, Denmark, desensitization, destination, discrimination, dissolve, distancing, diverge, divergence, divergent, DPA, driven, embed, ENHANZE, enjoining, ensuing, epinephrine, ESRD, ethnicity, evidenced, exemplified, exocrine, expert, fiercely, finite, Forbion, FORTUNE, fostered, fusion, FVC, gender, glomerular, gradually, graduate, graft, Great, Halozyme, halt, harassment, harder, Helsinki, hematopoietic, Hetero, home, hosted, hyaluronidase, idiopathic, IFR, ILD, immunosuppressant, inappropriate, innate, inside, Insider, insulin, interstitial, intimidation, intravenously, IPF, Japanese, journey, JP, JPMorgan, Karin, land, learn, legislature, lifted, ligand, lipoprotein, loved, Lundbeckfond, lysophosphatidic, lysosomal, mail, main, meant, mechanistic, median, mediate, mediated, MFN, MHRA, Miravo, MMF, mofetil, Morgan, mortality, mRSS, myasthenia, mycophenolate, nationwide, native, neuromuscular, neutralize, NMOSD, Northern, onset, opposed, optica, Orchard, organizational, orientation, OTC, outlook, output, overactivation, overexpressed, overproduce, overproduction, overstimulation, pandemic, parallel, Parliament, pathogenic, pause, paused, pDC, perspective, pharmacodynamic, pharmacokinetic, physical, physically, plasma, plasmacytoid, play, pledge, poor, postponed, practitioner, precaution, presidential, prioritization, prioritize, prolonged, race, Racial, ransomware, rapid, rationale, recharge, RECIPE, recourse, referencing, reimplement, reimplemented, relapsed, religion, remanded, remote, remotely, renovation, rental, reopen, reopening, repositioned, RiverVest, Rodnan, room, salivary, SC, scholarship, school, Seattle, segregation, sequester, setback, sexual, shape, shelter, Sherman, Shield, shortly, shut, signatory, skillset, slot, Sobi, Society, spectrum, stable, Stanley, steroid, strain, student, subcutaneously, subset, suggest, suggested, supervisory, surface, surgical, Swedish, tackle, tariff, TCA, tear, Teiripic, teleconference, telemedicine, temporarily, tender, threat, throat, tie, timeframe, timeline, tough, trajectory, tuition, unavailable, unchanged, unpurchased, upheld, Uplizna, vaccine, vast, vehicle, venture, veteran, VIB, Viela, Viridian, virtual, visit, vital, voluntarily, volunteer, volunteering, Washington, welfare, workplace, worsening
Removed: accretion, announce, antidrug, Aralez, Assent, bankrupt, BASF, Bishop, blend, blended, Blueprint, Bulletin, Carey, Chemie, Chile, Chimie, circumvent, citing, clarify, coated, compression, convincing, CSR, CU, dashboard, defaulting, deployed, derivative, disclosing, distributing, divested, Donald, effected, effectuated, endoscopic, England, erosive, expressly, FA, formulate, Halo, hybrid, illustrating, impressive, inconvenience, Innomar, instruct, intending, IPR, Journal, Lin, linear, linked, MassHealth, merged, Mexico, microspheronized, Minakem, mismatch, MRP, Mundipharma, negotiating, nerve, Nexium, ninety, Nonemployee, numbered, OCS, outlay, Pacific, persuasive, ph, Pharmacopeia, PMPRB, preceding, prevented, principle, proximal, PTAB, reach, reconcile, reinforce, renewing, retrospectively, Robert, Royal, Sanofi, Scandinavia, setting, sharing, shift, simplifying, sourced, Starnberg, strongly, supplying, Tianjin, Tianyao, today, transparent, trihydrate, twenty, typical, Uetikon, ulcer, unamortized, unaudited, unresponsive